View Item 

Show simple item record

Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2- negative breast cancer: A trajectory analysis of adverse events
dc.contributor.authorIp, Edward H.
dc.contributor.authorSaldana, Santiago
dc.contributor.authorMiller, Kathy D.
dc.contributor.authorCarlos, Ruth C.
dc.contributor.authorGareen, Ilana F.
dc.contributor.authorSparano, Joseph A.
dc.contributor.authorGraham, Noah
dc.contributor.authorZhao, Fengmin
dc.contributor.authorLee, Ju-Whei
dc.contributor.authorO’Connell, Nathaniel S.
dc.contributor.authorCella, David
dc.contributor.authorPeipert, John D.
dc.contributor.authorGray, Robert J.
dc.contributor.authorWagner, Lynne I.
dc.date.accessioned2022-01-06T15:47:57Z
dc.date.available2023-01-06 10:47:56en
dc.date.available2022-01-06T15:47:57Z
dc.date.issued2021-12-15
dc.identifier.citationIp, Edward H.; Saldana, Santiago; Miller, Kathy D.; Carlos, Ruth C.; Gareen, Ilana F.; Sparano, Joseph A.; Graham, Noah; Zhao, Fengmin; Lee, Ju-Whei ; O’Connell, Nathaniel S. ; Cella, David; Peipert, John D.; Gray, Robert J.; Wagner, Lynne I. (2021). "Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2- negative breast cancer: A trajectory analysis of adverse events." Cancer (24): 4546-4556.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/171125
dc.publisherWiley Periodicals, Inc.
dc.subject.otherbreast cancer
dc.subject.otheradverse events
dc.subject.otherdrug treatment
dc.subject.otherearly treatment discontinuation
dc.subject.otherpatient- reported outcome
dc.subject.otherperipheral neuropathy
dc.titleTolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2- negative breast cancer: A trajectory analysis of adverse events
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171125/1/cncr33992_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171125/2/cncr33992.pdf
dc.identifier.doi10.1002/cncr.33992
dc.identifier.sourceCancer
dc.identifier.citedreferenceThanarajasingam G, Leonard JP, Witzig TE, et al. Longitudinal toxicity over time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematol. 2020; 7: e490 - e497.
dc.identifier.citedreferenceMiller KD, O- Neill A, Gradishar W, et al. Double- blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node- positive and high- risk lymph node- negative breast cancer (E5103). J Clin Oncol. 2018; 36: 2621 - 2629.
dc.identifier.citedreferenceMiles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first- line treatment of human epidermal growth factor receptor 2- negative metastatic breast cancer. J Clin Oncol. 2010; 28: 3239 - 3247.
dc.identifier.citedreferenceRobert NJ, Diéras V, Glaspy J, et al. RIBBON- 1: randomized, double- blind, placebo- controlled, phase III trial of chemotherapy with or without bevacizumab for first- line treatment of human epidermal growth factor receptor 2- negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011; 29: 1252 - 1260.
dc.identifier.citedreferenceMiles D, Cameron D, Bondarenko I, et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first- line therapy for HER2- negative metastatic breast cancer (MERiDiAN): a double blind placebo- controlled randomised phase III trial with prospective biomarker evaluation. Eur J Cancer. 2017; 70: 146 - 155.
dc.identifier.citedreferencevon Minckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second- line treatment for patients with HER2- negative locally recurrent or metastatic breast cancer after first- line treatment with bevacizumab plus chemotherapy (TANIA): an open- label, randomised phase 3 trial. Lancet Oncol. 2014; 15: 1269 - 1278.
dc.identifier.citedreferenceBrufsky AM, Hurvitz S, Perez E, et al. RIBBON- 2: a randomized, double- blind, placebo- controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second- line treatment of human epidermal growth factor receptor 2- negative metastatic breast cancer. J Clin Oncol. 2011; 29: 4286 - 4293.
dc.identifier.citedreferenceMiller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666 - 2676.
dc.identifier.citedreferenceJubb AM, Miller KD, Rugo HS, et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res. 2011; 17: 372 - 381.
dc.identifier.citedreferenceRoviello G, Generali D, Sobhani N. The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2- negative breast cancer- a commentary on the E5103 randomized phase III clinical study. Transl Cancer Res. 2019; 8 ( suppl 2 ): S94 - S96.
dc.identifier.citedreferenceSchneider BP, Shen F, Jiang G, et al. Impact of genetic ancestry on outcomes in ECOG- ACRIN- E5103. JCO Precis Oncol. 2017; 2017: PO.17.00059. doi: 10.1200/PO.17.00059
dc.identifier.citedreferenceCoster S, Poole K, Fallowfield LJ. The validation of a quality of life scale to assess the impact of arm morbidity in breast cancer patients post- operatively. Breast Cancer Res Treat. 2001; 68: 273 - 282.
dc.identifier.citedreferenceIp EH, Zhang Q, Rejeski WJ, Harris TB, Kritchevsky S. Partially ordered mixed hidden Markov model for the disablement process of older adults. J Am Stat Assoc. 2013; 108: 370 - 380.
dc.identifier.citedreferenceIp EH, Zhang Q, Schwartz R, et al. Multi- profile hidden Markov model for mood, dietary intake, and physical activity in an intervention study of childhood obesity. Stat Med. 2013; 32: 3314 - 3331.
dc.identifier.citedreferenceRejeski WJ, Ip EH, Bertoni A, et al. Lifestyle change and mobility in aging obese adults with type 2 diabetes. N Engl J Med. 2012; 366: 1209 - 1217.
dc.identifier.citedreferenceGressett SM, Shah SR. Intricacies of bevacizumab- induced toxicities and their management. Ann Pharmacother. 2009; 43: 490 - 501.
dc.identifier.citedreferenceGullo G, Eustace AJ, Canonici A, et al. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early- stage HER- 2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08- 10 trial. Ther Adv Med Oncol. 2019; 11: 1 - 9. doi: 10.1177/1758835919864236
dc.identifier.citedreferenceWong ML, Gao J, Thanarajasingam G, et al. Expanding beyond maximum grade: chemotherapy toxicity over time by age and performance status in advanced non- small cell lung cancer in CALGB 9730 (Alliance A151729). Oncologist. Published online September 20, 2020. doi: 10.1002/onco.13527
dc.identifier.citedreferenceBasch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009; 101: 1624 - 1632.
dc.identifier.citedreferenceBasch E, Abernethy AP, Mullins D, et al. Recommendations for incorporating patient- reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012; 30 ( 34 ): 4249 - 4255.
dc.identifier.citedreferenceBasch E, Rogak LJ, Dueck AC. Methods for implementing and reporting patient- reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. Clin Ther. 2016; 38: 821 - 830.
dc.identifier.citedreferenceDi Maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015; 33: 910 - 915.
dc.identifier.citedreferenceBasch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire- based study. Lancet Oncol. 2006; 7: 903 - 909.
dc.identifier.citedreferenceBasch E, Wilfong L, Schrag D. Adding patient- reported outcomes to Medicare’s oncology value- based payment model. JAMA. 2020; 323: 213 - 214.
dc.identifier.citedreferenceKluetz PG, Kanapuru BK, Lemery S, et al. Informing the tolerability of cancer treatments using patient- reported outcome measures: summary of an FDA and Critical Path Institute workshop. Value Health. 2018; 21: 742 - 747.
dc.identifier.citedreferenceEton DT, Cella D, Yost KJ, et al. A combination of distribution- and anchor- based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004; 57: 898 - 910.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr33992_am.pdf
Size:
439.2KB
Format:
PDF
View/Open
Name:
cncr33992.pdf
Size:
576.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.